- Home
- RYN vs MLTX Comparison
RYN vs MLTX Comparison
Compare RYN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- MLTX
- Stock Information
- Founded
- RYN 1926
- MLTX 2021
- Country
- RYN United States
- MLTX Switzerland
- Employees
- RYN N/A
- MLTX N/A
- Industry
- RYN Real Estate Investment Trusts
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- RYN Real Estate
- MLTX Health Care
- Exchange
- RYN Nasdaq
- MLTX Nasdaq
- Market Cap
- RYN 3.5B
- MLTX 2.8B
- IPO Year
- RYN N/A
- MLTX N/A
- Fundamental
- Price
- RYN $26.11
- MLTX $51.99
- Analyst Decision
- RYN Hold
- MLTX Strong Buy
- Analyst Count
- RYN 4
- MLTX 7
- Target Price
- RYN $27.75
- MLTX $74.83
- AVG Volume (30 Days)
- RYN 1.1M
- MLTX 514.5K
- Earning Date
- RYN 08-06-2025
- MLTX 08-05-2025
- Dividend Yield
- RYN 11.16%
- MLTX N/A
- EPS Growth
- RYN 388.23
- MLTX N/A
- EPS
- RYN 4.91
- MLTX N/A
- Revenue
- RYN $1,240,027,000.00
- MLTX N/A
- Revenue This Year
- RYN N/A
- MLTX N/A
- Revenue Next Year
- RYN $3.44
- MLTX N/A
- P/E Ratio
- RYN $5.27
- MLTX N/A
- Revenue Growth
- RYN 22.69
- MLTX N/A
- 52 Week Low
- RYN $21.84
- MLTX $31.42
- 52 Week High
- RYN $32.88
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- RYN 73.40
- MLTX 51.30
- Support Level
- RYN $23.14
- MLTX $51.08
- Resistance Level
- RYN $26.17
- MLTX $53.78
- Average True Range (ATR)
- RYN 0.56
- MLTX 2.24
- MACD
- RYN 0.21
- MLTX -0.48
- Stochastic Oscillator
- RYN 94.06
- MLTX 47.66
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.